Fresenius Kabi Weighs Potential Of Warning Letter For Melrose Park

Deficient Plant A Significant Issue For Kabi

Fresenius Kabi discussed the latest around the potential of an FDA warning letter at its key injectables plant in Melrose Park, after earlier this year confirming that no product launches from the site were anticipated in 2021.

Fresenius Kabi
“We continue to believe that it’ll take a physical inspection to resolve the issue” - Kabi • Source: Shutterstock

Fresenius Kabi has warned that the potential of a US Food and Drug Administration warning letter against its large-scale sterile injectables plant in Melrose Park near Chicago “cannot be excluded,” while stressing that it is by no means a “given that we are going to receive one.”

Last year, an FDA inspection at Melrose Park revealed multiple Form 483 deficiencies, including a failure to properly deal with...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Manufacturing

More from Business